Skip to content
Open access · CC-BY via OpenAlex

Metformin attenuates H<sub>2</sub>O<sub>2</sub>‑induced osteoblast apoptosis by regulating SIRT3 via the PI3K/AKT pathway

Keda Yang, Lei Pei, Siming Zhou, Lin Tao, Yue Zhu

Experimental and Therapeutic Medicine · 2021 · ▲ 41 citations

Abstract

Osteoporosis is a common metabolic disease that has a high incidence in postmenopausal women. Studies have indicated that oxidative damage plays an important role in the development of postmenopausal osteoporosis. Metformin has been showed to have the ability to relieve excessive oxidation. The aim of the present was to determine the therapeutic effect and potential mechanism of metformin in postmenopausal osteoporosis. Oxidative damage was stimulated <em>in vitro</em> by the addition of H<sub>2</sub>O<sub>2</sub> to MC3T3‑E1 cells and a mouse menopausal model was also constructed. Cell viability and flow cytometry experiments were performed to determine the effects of H<sub>2</sub>O<sub>2</sub> and metformin treatment on apoptosis. Mitochondrial membrane potential was tested by JC‑1 assays. Western blotting was used to detect the expression of mitochondrial apoptosis markers and antioxidant enzymes. Small interfering RNA was used to knockdown sirtuin3 (SIRT3), which was verified at the mRNA and protein levels. Bilateral ovariectomy was used to prepare menopausal mice, which were analyzed using micro‑computed tomography. The results indicated that metformin is able to repair mitochondrial damage and inhibit the apoptosis of osteoblasts induced by H<sub>2</sub>O<sub>2</sub>, and also reverse bone mass loss in ovariectomized mice. Western blotting results demonstrated the involvement of SIRT3 in the production of antioxidant enzymes that are essential in protecting against mitochondrial injury. In addition, experiments with SIRT3 knockdown indicated that metformin reverses H<sub>2</sub>O<sub>2</sub>‑induced osteoblast apoptosis by upregulating the expression of SIRT3 via the PI3K/AKT pathway. The results of the present reveal the pathogenesis of oxidative damage and the therapeutic effect of metformin in postmenopausal osteoporosis. They also suggest that SIRT3 is a potential drug target in the treatment of osteoporosis, with metformin being a candidate drug for modification and/or clinical application.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.3892/etm.2021.10751
Canonical
link ↗
Fetched
2026-06-14 MST

Cite this

APA
Yang, K., Pei, L., Zhou, S., Tao, L., &amp; Zhu, Y. (2021). Metformin attenuates H<sub>2</sub>O<sub>2</sub>‑induced osteoblast apoptosis by regulating SIRT3 via the PI3K/AKT pathway. <em>Experimental and Therapeutic Medicine</em>. https://doi.org/10.3892/etm.2021.10751
Vancouver
Yang K, Pei L, Zhou S, Tao L, Zhu Y. Metformin attenuates H<sub>2</sub>O<sub>2</sub>‑induced osteoblast apoptosis by regulating SIRT3 via the PI3K/AKT pathway. Experimental and Therapeutic Medicine. 2021. doi:10.3892/etm.2021.10751.
BibTeX
@article{keda2021Metfor, title = {Metformin attenuates H<sub>2</sub>O<sub>2</sub>‑induced osteoblast apoptosis by regulating SIRT3 via the PI3K/AKT pathway}, author = {Keda Yang and Lei Pei and Siming Zhou and Lin Tao and Yue Zhu}, journal = {Experimental and Therapeutic Medicine}, year = {2021}, doi = {10.3892/etm.2021.10751}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings